The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy- pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1312-1318

  Prié, Stéphane ^a   Leung, Tack Ki ^a   Cernacek, Peter ^a   Ryan, James W ^b   Dupuis, Jocelyn ^a,c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; MONOCROTALINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CELL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASCULAR ENDOTHELIUM;

ADMINISTRATION, ORAL; ANIMALS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; PEPTIDYL-DIPEPTIDASE A; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; VENTRICULAR FUNCTION, RIGHT;

EID: 14444283145     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ABRAHAM, W. T., RAYNOLDS, M. V., GOTTSCHALL, B., BADESCH, D. B., WYNNE, K. M., GROVES, B. M., LOWES, B. D., BRISTOW, M. R., PERRYMAN, M. B. AND VOELKEL, N. F.: Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 86: suppl I, I-9-I-15, 1995.
2. ARAI, H., HORI, S., ARAMORI, I., OHKUBO, H. AND NAKANISHI, S.: Cloning and expression of a cDNA encoding an endothelin receptor. nature (Lond.) 348: 730-732, 1990.
3. BATTISTINI, B., CHAILLER, P., D'ORLÉANS-JUSTE, P., BRIÈRE, N. AND SIROIS, P.: Growth regulatory properties of endothelins. Peptides 14: 385-399, 1993.
4. CATRAVAS, J. D. AND WHITE, R. E.: Kinetics of pulmonary angiotensin-converting enzyme and 5′-nucleotidase in vivo. J. Appl. Physiol. 57: 1173-1181, 1984.
5. CHUA, B. H., KREBS, C. J., CHUA, C. C. AND DIGLIO, C. A.: Endothelin stimulates protein synthesis in smooth muscle cells. Am. J. Physiol. 262: E412-E416, 1992.
6. CODY, R. J., HAAS, G. J., BINKLEY, P. F., CAPERS, Q. AND KELLEY, R.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.
7. DE NUCCI, G., THOMAS, R., D'ORLÉANS-JUSTE, P., ANTUNES, E., WALDER, C., WARNER, T. D. AND VANE, J. R.: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U.S.A. 85: 9797-9800, 1988.
8. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am. J Physiol. 269: L690-L697, 1995.
9. DOHI, Y. AND LÜSCHER, T. F.: Endothelin in hypertensive resistance arteries. Intraluminal extraluminal dysfunction. Hypertension 18: 543-549, 1991.
10. B receptors. J. Appl. Physiol. 81: 1510-1515, 1996.
11. DUPUIS, J., GORESKY, C. A., RYAN, J. W., ROULEAU, J. L. AND BACH, G. G.: Pulmonary angiotensin-converting enzyme substrate hydrolysis during exercise. J. Appl. Physiol. 72: 1868-1886, 1992.
12. DUPUIS, J., GORESKY, C. A. AND STEWART, D. J.: Pulmonary removal and production of endothelin in the anesthetized dog. J. Appl. Physiol. 76: 694-700, 1994.
13. GIAID, A. AND SALEH, D.: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333: 214-221, 1995.
14. GIAID, A., YANAGISAWA, M., LANGLEBEN, D., MICHEL, R. P., LEVY, R., SHENNIB, H., KIMURA, S., MASAKI, T., DUGUID, WP. AND STEWART, D. J.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328: 1732-1739, 1993.
15. GRIFFITH, S. L., RHOADES, R. A. AND PACKER, C. S.: Pulmonary arterial smooth muscle contractility in hypoxia-induced pulmonary hypertension. J. Appl. Physiol. 77: 406-414, 1994.
16. ISHIKAWA, K., HASHIMOTO, H., MITANI, S., TOKI, Y., OKUMURA, K. AND ITO, T.: Enalapril improves heart failure induced by monocrotaline without reducing pulmonary hypertension in rats: Roles of preserved myocardial creatine kinase and lactate dehydrogenase isoenzymes. Int. J. Cardiol. 47: 225-233, 1995.
17. ISHIKAWA, K. I., HIDAI, C., OKUDA, C., KIMATA, S. I., MATSUOKA, R., HOSODA, S., QUERTERMOUS, T. AND KAWANA, M.: Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J. Am. Coll. Cardiol. 27: 1286-1291, 1996.
18. ITO, K., HAYASHI, K., NAKASHIMA, T. AND MURAKAMI, T.: Alteration of fate of vasoactive autacoids in pulmonary circulation following monocrotaline-induced lung vascular injury in rats. Br. J. Pharmacol. 94: 1167-1174, 1988.
19. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89: 2198-2203, 1994.
20. JACKSON, R. M., NARKATES, A. J. AND OPARIL, S.: Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia. J. Appl. Physiol. 60: 1121-1127, 1986.
21. MATHEW, R., GUZOWSKI, D. E. AND GLOSTER, E. S.: Effect of verapamil on monocrotaline-induced pulmonary artery hypertension and endothelial cell dysfunction in rats. Exp. Lung Res. 16: 627-644, 1990.
22. MCCORMICK, J. R., CHRZANOWSKI, R., ANDREANI, J. AND CATRAVAS, J. D.: Early pulmonary endothelial enzyme dysfunction after phorbol ester in conscious rabbits. J. Appl. Physiol. 63: 1972-1978, 1987.
23. MIYAUCHI, T., YORIKANE, R., SAKAI, S., SAKURAI, T., OKADA, M., NISHIKIBE, M., YANO, M., YAMAGUCHI, I., SUGISHITA, Y. AND GOTO, K.: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. 73: 887-897, 1993.
24. MOALLI, R., PITT, B. R. AND GILLIS, C. N.: Effect of flow and surface area on angiotensin-converting enzyme activity in rabbit lungs. J. Appl. Physiol. 62: 2042-2050, 1987.
25. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm. Pharmacol. Lett. 2: 90-92, 1996.
26. ONO, S., WESTCOTT, J. Y. AND VOEKEL, N. F.: PAF antagonists inhibit pulmonary vascular remodelling induced by hypobaric hypoxia in rats. J. Appl. Physiol. 73: 1084-1092, 1992.
27. PITT, B. R., LISTER, G., DAVIES, P. AND REID, L.: Correlation of pulmonary ACE activity and capillary surface area during postnatal development. J. Appl. Physiol. 62: 2031-2041, 1987.
28. RASCHACK, M., UNGER, L., RIECHERS, H. AND KLINGE, D.: Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J. Cardiovasc. Pharmacol. 26: suppl III, III-397-III-399, 1995.
29. RIECHERS, H., ALBRECHT, H. P., AMBERG, W., BAUMANN, E., BERNARD, H., BÖHM, H. J., KLINGE, A., KLING, A., MÜLLER, S., RASCHACK, M., UNGER, L., WALKER, N. AND WERNET, W.: Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J. Med. Chem. 39: 2123-2128, 1996.
30. ROTH, R. A. AND REINDEL, J. F.: Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. In Advances in Experimental Medicine & Biology, Biological Reactive Intermediates IV, ed. by Witner C. M. et al., pp. 477-487, Plenum Press, New York, 1990.
31. SAKURAI, T., YANAGISAWA, M. AND MASAKI, T.: Molecular characterization of endothelin receptors. Trends. Pharmacol. Sci. 13: 103-108, 1992.
32. SHIBA, R., YANAGISAWA, M., MIYAUCHI, T., ISHII, Y., KIMURA, S., UCHIYAMA, Y., MASAKI, T. AND GOTO, K.: Elimination of intravenously injected endothelin-1 from the circulation of the rat. J. Cardiovasc. Pharmacol. 13: suppl V, V-98-V101, 1989.
33. STEWART, D. J., LEVY, R. D., CERNACEK, P. AND LANGLEBEN, D.: Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann. Intern. Med. 114: 464-469, 1991.
34. B receptors mediate vascular smooth muscle contraction. Br. J. Pharmacol. 107: 858-860, 1992.
35. TOIVONEN, H. J. AND CATRAVAS, J. D.: Effects of alveolar pressure on lung angiotensin-converting enzyme function in vivo. J. Appl. Physiol. 61: 1041-1050, 1986.
36. TSUTAMOTO, T., WADA, A., MAEDA, Y., ADACHI, T. AND KINOSHITA, M.: Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J. Am. Coll. Cardiol. 23: 1427-1433, 1994.
37. VANE, J.: Endothelins come home to roost. Nature (Lond.) 348: 673-675, 1990.
38. YOSHIBAYASHI, M., NISHIOKA, K., NAKAO, K., SAITO, Y., MATSUMURA, M., UEDA, T., TEMMA, S., SHIRAKAMI, G., IMURA, H. AND MIKAWA, H.: Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84: 2280-2285, 1991.
39. A receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respiratory Cell. & Molecular Biology 9(4): 429-433, 1993.